Product Description
a therapeutic antibody that binds to the Insulin-like Growth Factor 1 Receptor (IGF-1R)
Mechanisms of Action: IGF Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer|Hepatocellular Carcinoma
Phase 1: Multiple Myeloma|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2006-005978-51 |
2006-005978-51 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2009-12-21 |
2022-03-12 |
Treatments |
|
NCT01233895 |
TED6420 | P1 |
Completed |
Multiple Myeloma |
2008-09-01 |
2019-03-19 |
Treatments |
|
2008-000810-54 |
2008-000810-54 | P2 |
Completed |
Breast Cancer |
2010-11-10 |
2022-03-12 |
Treatments |
|
NCT00774878 |
TCD10631 | P2 |
Terminated |
Breast Cancer |
2010-11-01 |
2019-03-18 |
Treatments |
|
NCT00791544 |
TED10630 | P2 |
Terminated |
Hepatocellular Carcinoma |
2009-11-01 |
2019-03-18 |
Treatments |